Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03208660
Recruitment Status : Completed
First Posted : July 5, 2017
Last Update Posted : April 11, 2019
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
This study is conducted to assess the retention rate of Fycompa when given in routine clinical care.

Condition or disease Intervention/treatment
Epilepsy Drug: Fycompa

Layout table for study information
Study Type : Observational
Actual Enrollment : 2000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
Actual Study Start Date : April 7, 2017
Actual Primary Completion Date : March 15, 2019
Actual Study Completion Date : March 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy
Drug Information available for: Perampanel

Group/Cohort Intervention/treatment
Fycompa
Participants diagnosed with epilepsy and treated with Fycompa
Drug: Fycompa
Oral suspension
Other Name: Perampanel




Primary Outcome Measures :
  1. Percentage of participants remaining on Fycompa treatment at specified time points after initiation of treatment (Retention rate) [ Time Frame: 3, 6, 12, 18, and 24 months ]
    Retention rate is the ratio of the number of participants remaining on Fycompa treatment to the number of participants who could have been exposed for that length of time.


Secondary Outcome Measures :
  1. Number of participants with a 50% response rate [ Time Frame: up to 24 months ]
    The response rate will be evaluated from seizure frequencies recorded in medical records or seizure diaries, where available. If not available, the investigator assessment of the therapeutic response will be used.

  2. Number of participants with a 75% response rate [ Time Frame: up to 24 months ]
    The response rate will be evaluated from seizure frequencies recorded in medical records or seizure diaries, where available. If not available, the investigator assessment of the therapeutic response will be used.

  3. Number of participants with a 100% response rate [ Time Frame: up to 24 months ]
    The response rate will be evaluated from seizure frequencies recorded in medical records or seizure diaries, where available. If not available, the investigator assessment of the therapeutic response will be used.

  4. Categorized percent reduction in seizure frequency from baseline [ Time Frame: Baseline, up to 24 months ]
    An epileptic seizure or seizure is a brief episode of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. The outward effect can vary from uncontrolled jerking movement (tonic-clonic seizure) to as subtle as a momentary loss of awareness (absence seizure).

  5. Median percent change in seizure frequency from baseline [ Time Frame: Baseline, up to 24 months ]
    An epileptic seizure or seizure is a brief episode of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. The outward effect can vary from uncontrolled jerking movement (tonic-clonic seizure) to as subtle as a momentary loss of awareness (absence seizure).

  6. Percentage of participants who had no change or a worsening of seizures from baseline [ Time Frame: Baseline, up to 24 months ]
    An epileptic seizure or seizure is a brief episode of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. The outward effect can vary from uncontrolled jerking movement (tonic-clonic seizure) to as subtle as a momentary loss of awareness (absence seizure).

  7. Total provider health care visits before, during, and after final dose of Fycompa [ Time Frame: 6 months before initiation of Fycompa to 6 months after last dose of Fycompa ]
    Total provider health care visits before, during, and after final dose of Fycompa will be summarized as a safety variable.

  8. Number of participants with any treatment-emergent (TE) serious adverse event (SAE) resulting in discontinuation of Fycompa [ Time Frame: Up to 24 months ]
    An SAE is any untoward medical occurrence that at any dose: results in death; is life threatening (ie, the participant was at immediate risk of death from the adverse events [AE] as it occurred; this does not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.

  9. Number of participants with any treatment-emergent adverse event (TEAE) resulting in discontinuation of Fycompa [ Time Frame: Up to 24 months ]
    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with the medicinal product. A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.

  10. Mean change in body weight from baseline [ Time Frame: Baseline, Up to 24 months ]
    Change from baseline is calculated as the post-baseline value minus the baseline value.

  11. Mean change in height of pediatric participants from baseline [ Time Frame: Baseline, Up to 24 months ]
    Change from baseline is calculated as the post-baseline value minus the baseline value.

  12. Maximum dose of Fycompa [ Time Frame: Up to 24 months ]
    The extent of exposure of Fycompa will be determined by summarizing the maximum dose of the study drug.

  13. Average dose of Fycompa [ Time Frame: Up to 24 months ]
    The extent of exposure of Fycompa will be determined by summarizing the average dose of the study drug.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Data will be obtained by reviewing the medical records of the participants with a diagnosis of epilepsy and treated with Fycompa on clinician's recommendation at up to approximately 40 epilepsy centers.
Criteria

Inclusion Criteria:

  • Participants must have met all of the following criteria to be included in this study:

    1. Diagnosis of epilepsy
    2. Initiated treatment with Fycompa at any time after 01 Jan 2014
    3. Provided written informed consent by the participant or the participant's legally authorized representative signed for the use of medical records (if required by an Institutional Review Board [IRB] or Independent Ethics Committee [IEC], or by regulatory authorities).

Exclusion Criteria:

  • Not applicable

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03208660


  Show 44 Study Locations
Sponsors and Collaborators
Eisai Inc.

Layout table for additonal information
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT03208660     History of Changes
Other Study ID Numbers: E2007-G000-506
First Posted: July 5, 2017    Key Record Dates
Last Update Posted: April 11, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eisai Inc.:
seizure
Fycompa
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases